ARA-290 Dosage Chart & Schedule
ARA-290 (cibinetide) is an 11-amino-acid peptide modeled on the helix-B region of erythropoietin. It selectively engages the innate repair receptor without stimulating red-cell production, and has been studied for neuropathic pain and tissue protection, notably in sarcoidosis-related small-fiber neuropathy. It is investigational.
In small clinical studies of small-fiber neuropathy, cibinetide (ARA-290) has most often been given as about 4 mg subcutaneously once daily for roughly 28 days. It is investigational and not an approved drug.
Figures describe how ARA-290 is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- Once daily
- Weekly total
- 7-14 mg/week
- Cycle
- ~28-day course
Lower amounts within the range of regimens explored in early research.
- Frequency
- Once daily
- Weekly total
- 28 mg/week
- Cycle
- ~28-day course
The dose most commonly reported in small-fiber neuropathy trials.
Selective repair receptor, not erythropoiesis
- ARA-290 engages the innate repair receptor (EPOR/CD131 heteromer) without stimulating red-cell production, unlike full-length erythropoietin.
- Plasma half-life is only minutes, but the tissue-protective signaling it triggers is studied over a longer window, which supports once-daily dosing.
Ready to run this protocol?
Dosing is only as good as the vial. Research-grade peptides are third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
Weekly schedule
A typical week on the trial-referenced protocol (Once daily).
Dosing day Off
From vial to injection in 6 steps
Wipe both vial tops
Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.
Draw the water
Pull the planned amount of bacteriostatic water (2 mL) into the syringe.
Add it slowly
Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.
Let it dissolve
Wait until the solution is fully clear, then refrigerate the vial.
Draw your dose
Pull the calculated units on a U-100 insulin syringe.
Store between uses
Keep the reconstituted vial refrigerated and use within its stable window.
Handling & storage
- A 4 mg vial reconstituted with 2 mL of bacteriostatic water gives 2 mg/mL; a 2 mg vial with 1 mL gives the same concentration.
- At 2 mg/mL, a 4 mg dose is 2 mL and a 1 mg dose is 0.5 mL (50 units on a U-100 syringe).
- Keep the reconstituted vial refrigerated and inspect for clarity before use.
- Investigational compound; not approved for treating any condition.
ARA-290 dosing FAQ
What ARA-290 dose is used in research?
Clinical studies in small-fiber neuropathy most often used about 4 mg subcutaneously once daily for roughly 28 days.
Why is it dosed daily if the half-life is only minutes?
The peptide clears quickly, but it acts as a trigger for downstream tissue-protective signaling that outlasts the molecule, so once-daily dosing is the common trial pattern.
How is a 4 mg vial reconstituted?
Adding 2 mL of bacteriostatic water yields 2 mg/mL, which conveniently makes the whole 2 mL a single 4 mg dose.
Is ARA-290 approved?
No. It is investigational; the dosing above reflects study protocols, not a treatment recommendation.
Sources
Categories: Healing & Recovery · Status: Approved (see notes). This page is educational and for laboratory research use only; it is not medical advice.